Literature DB >> 11370802

A novel preclinical model of human malignant melanoma utilizing bioreactor rotating-wall vessels.

L L Licato1, V G Prieto, E A Grimm.   

Abstract

Malignant melanoma poses a serious health risk which is becoming more crucial as the incidence of this disease steadily increases. The development of appropriate in vitro models that reflect the in vivo tumor environment is a key factor for the study of this malignancy. The local tumor microenvironment plays a critical role in the ability of tumor cells to proliferate and metastasize. While interactions among various cell types are known to be important for tumor growth, most in vitro models utilize only tumor cells, ignoring the importance of tumor-stroma interactions, as well as the contribution of immune cells, which may be important for potential therapies. In addition, the cellular architecture found in vivo, known to be involved in changes in gene expression, is not reflected in standard two-dimensional culture systems. In this study, we have utilized rotating-vessel bioreactors to culture minced human melanoma specimens, allowing the culture of three-dimensional structures which reflect the cellular architecture and heterogeneous composition of the tumor site in vivo. The viability of the pieces in culture can be maintained for 1-2 wk. Immunohistochemical analysis shows multiple cellular types similar to the in vivo situation. Therefore, this system provides a unique model of human melanoma that mimics the in vivo tumor environment much more closely than current culture methods. This novel system may be utilized to determine the mechanism of action of current therapy protocols, as well as to develop new treatment regimens.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11370802     DOI: 10.1290/1071-2690(2001)037<0121:ANPMOH>2.0.CO;2

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol Anim        ISSN: 1071-2690            Impact factor:   2.723


  24 in total

1.  Morphologic differentiation of colon carcinoma cell lines HT-29 and HT-29KM in rotating-wall vessels.

Authors:  T J Goodwin; J M Jessup; D A Wolf
Journal:  In Vitro Cell Dev Biol       Date:  1992-01

2.  Human melanoma progression in skin reconstructs : biological significance of bFGF.

Authors:  F Meier; M Nesbit; M Y Hsu; B Martin; P Van Belle; D E Elder; G Schaumburg-Lever; C Garbe; T M Walz; P Donatien; T M Crombleholme; M Herlyn
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

3.  Correlation of histology and drug response of human tumors grown in native-state three-dimensional histoculture and in nude mice.

Authors:  R A Vescio; K M Connors; T Kubota; R M Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-15       Impact factor: 11.205

4.  Rotating-wall vessel coculture of small intestine as a prelude to tissue modeling: aspects of simulated microgravity.

Authors:  T J Goodwin; W F Schroeder; D A Wolf; M P Moyer
Journal:  Proc Soc Exp Biol Med       Date:  1993-02

Review 5.  The treatment of metastatic melanoma with chemotherapy and biologics.

Authors:  M B Atkins
Journal:  Curr Opin Oncol       Date:  1997-03       Impact factor: 3.645

Review 6.  Tissue structure, nuclear organization, and gene expression in normal and malignant breast.

Authors:  M J Bissell; V M Weaver; S A Lelièvre; F Wang; O W Petersen; K L Schmeichel
Journal:  Cancer Res       Date:  1999-04-01       Impact factor: 12.701

7.  Cell-cycle arrest versus cell death in cancer therapy.

Authors:  T Waldman; Y Zhang; L Dillehay; J Yu; K Kinzler; B Vogelstein; J Williams
Journal:  Nat Med       Date:  1997-09       Impact factor: 53.440

8.  Hormonal modulation of Ishikawa cells during three-dimensional growth in vitro.

Authors:  D M Pinelli; J Drake; M C Williams; D Cavanagh; J L Becker
Journal:  J Soc Gynecol Investig       Date:  1998 Jul-Aug

9.  Prognostic factors in 1,521 melanoma patients with distant metastases.

Authors:  A Barth; L A Wanek; D L Morton
Journal:  J Am Coll Surg       Date:  1995-09       Impact factor: 6.113

Review 10.  Prospects for use of microgravity-based bioreactors to study three-dimensional host-tumor interactions in human neoplasia.

Authors:  J M Jessup; T J Goodwin; G Spaulding
Journal:  J Cell Biochem       Date:  1993-03       Impact factor: 4.429

View more
  7 in total

1.  Microgravity assay of neuroblastoma: in vitro aggregation kinetics and organoid morphology correlate with MYCN expression.

Authors:  Robert A Redden; Edward J Doolin
Journal:  In Vitro Cell Dev Biol Anim       Date:  2011-03-08       Impact factor: 2.416

Review 2.  Using space-based investigations to inform cancer research on Earth.

Authors:  Jeanne L Becker; Glauco R Souza
Journal:  Nat Rev Cancer       Date:  2013-04-12       Impact factor: 60.716

3.  An update to space biomedical research: tissue engineering in microgravity bioreactors.

Authors:  Abolfazl Barzegari; Amir Ata Saei
Journal:  Bioimpacts       Date:  2012-03-16

4.  Generation of a tumor spheroid in a microgravity environment as a 3D model of melanoma.

Authors:  Bernadette Marrero; Jane L Messina; Richard Heller
Journal:  In Vitro Cell Dev Biol Anim       Date:  2009-06-16       Impact factor: 2.416

Review 5.  Biomechanical forces in the skeleton and their relevance to bone metastasis: biology and engineering considerations.

Authors:  Maureen E Lynch; Claudia Fischbach
Journal:  Adv Drug Deliv Rev       Date:  2014-08-29       Impact factor: 15.470

6.  Rotary bioreactor culture can discern specific behavior phenotypes in Trk-null and Trk-expressing neuroblastoma cell lines.

Authors:  Robert A Redden; Radhika Iyer; Garrett M Brodeur; Edward J Doolin
Journal:  In Vitro Cell Dev Biol Anim       Date:  2014-01-30       Impact factor: 2.416

Review 7.  The Fight against Cancer by Microgravity: The Multicellular Spheroid as a Metastasis Model.

Authors:  Daniela Grimm; Herbert Schulz; Marcus Krüger; José Luis Cortés-Sánchez; Marcel Egli; Armin Kraus; Jayashree Sahana; Thomas J Corydon; Ruth Hemmersbach; Petra M Wise; Manfred Infanger; Markus Wehland
Journal:  Int J Mol Sci       Date:  2022-03-12       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.